Characteristics of responders and nonresponders to Epo/G-CSF treatment
| . | Responders . | Nonresponders . | P* . |
|---|---|---|---|
| No. patients | 18 | 28 | |
| Median age, y (range) | 69 (47-87) | 68 (40-90) | .964 |
| Sex, M/F | 10/8 | 20/8 | |
| WHO 2001, n (%)† | .248 | ||
| RA(RS) | 8 (44) | 10 (36) | |
| RCMD(RS) | 10 (56) | 16 (57) | |
| RAEB-1 | 1 (3.5) | ||
| MDS-U | 1 (3.5) | ||
| IPSS, n (%)† | .183 | ||
| Low | 12 (67) | 13 (46) | |
| Intermediate-I | 6 (33) | 15 (54) | |
| Median WPSS (range) | < .001 | ||
| Very low | 5 (28) | 0 (0) | |
| Low | 11 (61) | 11 (39) | |
| Intermediate | 2 (11) | 11 (39) | |
| High | 5 (18) | ||
| Not classifiable | 1 (3.5) | ||
| Previous transfusion support, number of patients (%)† | 2 (12) | 18 (62) | .010 |
| Median blast percentage (range) | 1.9 (0.6-4.2) | 2.2 (0.5-9.7) | .257 |
| Median Hb, mmol/L (range) | 5.9 (4.8-6.3) | 5.1 (4.1-6.6) | .001 |
| Median time from diagnosis to study entry, mo (range) | 0 (0-58) | 0 (0-78) | .426 |
| Median serum Epo at study entry, U/L (range) | 76 (19-587) | 187 (33-6000) | .001 |
| Median ferritin at study entry, mg/L (range) | 576 (47-1992) | 786 (47-3543) | .168 |
| Median LDH at study entry, U/L (range) | 341 (192-569) | 350 (205-2599) | .276 |
| Aberrant flow cytometry, n (%)† | 2 (11%) | 21 (72%) | < .001 |
| . | Responders . | Nonresponders . | P* . |
|---|---|---|---|
| No. patients | 18 | 28 | |
| Median age, y (range) | 69 (47-87) | 68 (40-90) | .964 |
| Sex, M/F | 10/8 | 20/8 | |
| WHO 2001, n (%)† | .248 | ||
| RA(RS) | 8 (44) | 10 (36) | |
| RCMD(RS) | 10 (56) | 16 (57) | |
| RAEB-1 | 1 (3.5) | ||
| MDS-U | 1 (3.5) | ||
| IPSS, n (%)† | .183 | ||
| Low | 12 (67) | 13 (46) | |
| Intermediate-I | 6 (33) | 15 (54) | |
| Median WPSS (range) | < .001 | ||
| Very low | 5 (28) | 0 (0) | |
| Low | 11 (61) | 11 (39) | |
| Intermediate | 2 (11) | 11 (39) | |
| High | 5 (18) | ||
| Not classifiable | 1 (3.5) | ||
| Previous transfusion support, number of patients (%)† | 2 (12) | 18 (62) | .010 |
| Median blast percentage (range) | 1.9 (0.6-4.2) | 2.2 (0.5-9.7) | .257 |
| Median Hb, mmol/L (range) | 5.9 (4.8-6.3) | 5.1 (4.1-6.6) | .001 |
| Median time from diagnosis to study entry, mo (range) | 0 (0-58) | 0 (0-78) | .426 |
| Median serum Epo at study entry, U/L (range) | 76 (19-587) | 187 (33-6000) | .001 |
| Median ferritin at study entry, mg/L (range) | 576 (47-1992) | 786 (47-3543) | .168 |
| Median LDH at study entry, U/L (range) | 341 (192-569) | 350 (205-2599) | .276 |
| Aberrant flow cytometry, n (%)† | 2 (11%) | 21 (72%) | < .001 |
The data of some patients (25/46, ie, 9 RA[RS], 14 RCMD[RS], 1 RAEB-1, and 1 MDS-U) were used in a previous study.13
Epo indicates erythropoietin; F, female; G-CSF, granulocyte-colony-stimulating factor; Hb, hemoglobin; IPSS, international prognostic scoring system; LDH, lactate dehydrogenase; M, male; MDS, myelodysplastic syndromes; MDS-U, myelodysplastic syndrome, unclassified; RA, refractory anemia; RAEB-1 or RAEB-2, refractory anemia with excess blasts type 1 or 2; RCMD, refractory anemia; RS, ring sideroblasts; and WPSS, World Health Organization-based prognostic scoring system.
P values indicate comparison between responders and nonresponders.
Percentages in parentheses depict percentage of cases within responder or nonresponder group.